Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. - Wikidata - wikimedia - TriplyDB

Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain.

Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain.

http://www.wikidata.org/entity/Q34785937

about

Botulinum toxins for the prevention of migraine in adults Neuromodulators for pain management in rheumatoid arthritis Neuromodulators for pain management in rheumatoid arthritis Botulinum toxin for shoulder pain SNAP-23 and VAMP-3 contribute to the release of IL-6 and TNFα from a human synovial sarcoma cell line Recommendations for the pharmacological management of neuropathic pain: an overview and literature update Current status and future directions of botulinum neurotoxins for targeting pain processing OnabotulinumtoxinA for trigeminal neuralgia: a review of the available data Botulinum Toxin for Neuropathic Pain: A Review of the Literature Translational investigation and treatment of neuropathic pain Botulinum Toxin Type A for the Treatment of Neuropathic Pain in Neuro-Rehabilitation Complications of compressive neuropathy: prevention and management strategies The Potential Role of Sensory Testing, Skin Biopsy, and Functional Brain Imaging as Biomarkers in Chronic Pain Clinical Trials: IMMPACT Considerations.Botulinum toxin-A treatment reduces human mechanical pain sensitivity and mechanotransduction.Chronic migraine--classification, characteristics and treatment.EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.Blockade of glutamate release by botulinum neurotoxin type A in humans: a dermal microdialysis study.Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains.Guidance on the management of pain in older people.Therapeutic use of botulinum toxin in migraine: mechanisms of action.Intraarticular botulinum toxin A for refractory painful total knee arthroplasty: a randomized controlled trial.Botulinum toxin therapy for osteoarticular pain: an evidence-based review Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society.Efficacy of botulinum toxin type a for treating chronic low back pain Increased levels of SV2A botulinum neurotoxin receptor in clinical sensory disorders and functional effects of botulinum toxins A and E in cultured human sensory neurons.Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine.Botulinum toxin in migraine: Role of transport in trigemino-somatic and trigemino-vascular afferents.A review of thoracic outlet syndrome and the possible role of botulinum toxin in the treatment of this syndrome Incobotulinum Toxin-A Improves Post-Surgical and Post-Radiation Pain in Cancer Patients.A clinical evaluation of botulinum toxin-A injections in the temporomandibular disorder treatment Botulinum toxin type A for neuropathic pain in patients with spinal cord injury.Sympathetic block with botulinum toxin to treat complex regional pain syndrome.Botulinum toxin injection and phenol nerve block for reduction of end-of-life pain Cutaneous neuroma physiology and its relationship to chronic pain.CSD, BBB and MMP-9 elevations: animal experiments versus clinical phenomena in migraine.Interventions for hemiplegic shoulder pain: systematic review of randomised controlled trials.Use of botulinum toxin in musculoskeletal pain.The effects of intradermal botulinum toxin type a injections on pain symptoms of patients with diabetic neuropathy.Pharmacological treatment of diabetic neuropathic pain.Review of current guidelines on the care of postherpetic neuralgia.

P2860

Q24186932-F65D1ABA-E852-415A-A085-DD5F787D0792 Q24203885-BC8F221B-E092-48C4-988B-34B7EF91BAA0 Q24235149-E11CE9B4-6AA9-43C4-97D2-E067BEFF090E Q24235542-3BA77CF0-3B25-416D-AB3A-754ABC8F9C85 Q24316444-BC8E0668-3E00-4773-91B1-6DA410F7C42A Q24616897-AF726E33-4DBC-469C-8437-4AF33703B055 Q26778129-5B87AA66-08D2-48E9-AFAD-A85859E619F6 Q26796286-FF48D496-B65C-40C9-A5A6-573CB8D4E69F Q26796604-71DEA3A3-69FD-4976-B828-FD85E7298CB9 Q27011346-66CC9A64-FB1A-4DF7-92A4-4586972F9F2B Q28088625-7D5DB33E-E608-4E1A-9891-ECB2F91ABC1C Q28390742-6283E364-B888-487D-A93B-9631F73101F1 Q30235485-B7A0BCF7-332B-482E-9B0F-F7B3FC82370A Q33957870-2CD110CA-9987-4B2A-A646-5429B881D00B Q34030691-2856A059-49B4-43FD-A542-BD34857299D0 Q34110857-2674865F-968E-41F1-A5B1-D339518D9502 Q34154494-8F5F23A9-9491-46F5-85BE-17672C1E9A1D Q34207258-5C5B76D5-FB73-4DAD-A99C-3AECCC2D1E12 Q34328425-868BDC66-D143-46AD-ADD7-0F38AF753B67 Q34419654-173AB141-4C0E-426A-A7D9-A22AE8099CBA Q34479556-E5E109CD-BC4E-479A-91A2-467A827B91FF Q34554147-FED4248F-2923-46D3-984E-E08A18906E23 Q34756198-F0864127-FAB4-4A8A-9B35-77BA827B088C Q35105522-41DFA303-27B3-493F-9913-17F82B05C059 Q35548169-5C5A0A44-D3CB-4D25-825E-B293125E7C03 Q35681903-C0F50ED2-9FC3-411E-B9E4-D87D7390B337 Q35691221-EE9FAC65-DE4F-4B5F-81C1-898150C71848 Q36432805-A5C41C15-083D-419C-BB25-90B20BB6EBF5 Q36507209-396F7DAF-E804-4B0B-ACC1-57F46CA78E9F Q36510912-5AF91A3B-5FCE-4D1F-A00D-B598E269665A Q36780108-0D7BD8D3-0C62-4241-B602-5B657280A5D7 Q37391173-FC2F4971-394D-4C19-B04E-EB41C336101C Q37403903-8E182D81-5505-432F-8813-67FAC6D04A9B Q37501088-7CBAB3E8-5025-40BE-B989-37EE1C28E1C8 Q37630537-0633DBD9-F103-42F7-9F22-D9F605BC5A90 Q37670125-1C2B5129-3D9B-42D0-916B-FC5A53232036 Q37671002-08C00958-0264-48C5-A2DB-F9B2D5CA2CCD Q37723197-1B5C328C-56EC-448C-AE64-753EEC405B09 Q37858519-982B8323-E260-4268-8DE0-2B81C8D570A6 Q37929504-50309789-FADF-4EB9-BF22-F9A4405167CD

P2860

Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain.

http://www.wikidata.org/entity/Q34785937

description

2008 nî lūn-bûn

@nan

2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain.

@ast

Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain.

@en

Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain.

@nl

type

label

Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain.

@ast

Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain.

@en

Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain.

@nl

prefLabel

Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain.

@ast

Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain.

@en

Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain.

@nl

P1433

Q34785937-54E0A0B7-5D16-4404-9D6E-E6F5D0254558

P1476

Q34785937-360BE8F0-C2AE-4E42-AB97-250E9633BF65

P2093

Q34785937-2616AA24-22A1-45CD-918C-4B59572ADE27

Q34785937-67C6F182-790E-49FB-99B9-06A959AC5DBF

Q34785937-B13A6F1F-5D2B-4DCE-A4DF-6F36E36431CA

Q34785937-BDBFC6A9-76E2-423D-9B00-58AF7AF2C4DB

P2860

Q34785937-0C067D2A-87CD-4C22-BBB7-FA296F2E47DD

Q34785937-1BA994D2-9F52-4DF0-A6B6-562822A5C517

Q34785937-20BF4385-6F51-41A4-9A29-8E9CEC0277DB

Q34785937-2988F4CA-2210-4AB5-A9F3-D343294682F2

Q34785937-2B1EF4B9-8F58-40C1-BEB0-E69288FB3651

Q34785937-2BC000B2-621F-4429-B733-317E829E4A78

Q34785937-2D85D887-13AC-4F06-9FED-EE4930D929F1

Q34785937-3652BD3E-BA98-447A-A0AD-1AA2F4856AC8

Q34785937-386626CB-08ED-44AB-8B98-5888012F66BD

Q34785937-3B718904-3375-41FE-A3D9-EDF1616F6D82

P304

Q34785937-8E5695DC-472E-419B-AFA5-EF71571A1F76

P31

Q34785937-B8BF7D64-3378-4C66-B14B-4B1E2D316F1B

P356

Q34785937-EB466D2D-91C4-4622-9B7E-08DBB750A90A

P433

Q34785937-35B39393-F0C3-4614-9A42-550B19E373C0

P478

Q34785937-713E0E14-CAD9-493E-BCB3-F4E508DB99B6

P577

Q34785937-E5CF899A-DC2E-4803-AA70-DF681D95C266

P5875

Q34785937-86760E61-9BA2-428F-B310-94BE7AB1AF35

P698

Q34785937-875D6B63-9982-488E-A8E5-0506AA2509F1

P921

Q34785937-EFB6258C-6213-4377-BF52-64E59D1ED8FD

Q34785937-F32F360B-6F0C-4E84-9A1D-C0A71FD52791

Q34785937-f7cecf3f-5b9b-41f6-b581-9267026e2749

P356

P1433

Annals of Neurology

P1476

Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain.

@en

P2093

D Bouhassira

http://www.w3.org/2001/XMLSchema#string

Danièle Ranoux

http://www.w3.org/2001/XMLSchema#string

Francoise Morain

http://www.w3.org/2001/XMLSchema#string

Nadine Attal

http://www.w3.org/2001/XMLSchema#string

P2860

Analgesic therapy in postherpetic neuralgia: a quantitative systematic review.

The Epidemiology of Chronic Pain of Predominantly Neuropathic Origin. Results From a General Population Survey

The hospital anxiety and depression scale

Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy

Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity

Botulinum toxin A for axillary hyperhidrosis (excessive sweating).

Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin.

Postherpetic neuralgia: irritable nociceptors and deafferentation.

Epidemiology and treatment of neuropathic pain: the UK primary care perspective.

EFNS guidelines on pharmacological treatment of neuropathic pain.

P304

274-283

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ANA.21427

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P577

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5309515

http://www.w3.org/2001/XMLSchema#string

P698

18546285

http://www.w3.org/2001/XMLSchema#string

P921

neuropathic pain

chronic neuropathic pain